Dr. Odisho on a Risk Prediction Model in Renal Cell Carcinoma

Video

Anobel Odisho, MD, urologic oncology fellow, University of Washington, discusses the use of a risk prediction model for patients with renal cell carcinoma.

Anobel Odisho, MD, urologic oncology fellow, University of Washington, discusses the use of a risk prediction model for patients with renal cell carcinoma (RCC).

Though risk prediction models are generally prevalent in all of medicine and its corresponding research, they can be difficult to apply in a real world setting with patients and the community, Odisho explains.

Odisho and his colleagues thus set out to develop an interactive tool that can make the application of these nomograms more user-friendly. They used the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria, which is validated for patients with metastatic RCC, and created an interactive visualization that displays key criteria and allows a user to make selections and see results in real time. Not only can the user see each of the individual risk predictive factors, but he can also see each individual patient within a cohort, explains Odisho.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute